Is Fate Therapeutics Stock a Good Investment?
Fate Therapeutics Investment Advice | FATE |
- Examine Fate Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Fate Therapeutics' leadership team and their track record. Good management can help Fate Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Fate Therapeutics' business and its evolving consumer preferences.
- Compare Fate Therapeutics' performance and market position to its competitors. Analyze how Fate Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Fate Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Fate Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Fate Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Fate Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Fate Therapeutics Stock
Researching Fate Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.54. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.56. The entity had not issued any dividends in recent years.
To determine if Fate Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fate Therapeutics' research are outlined below:
| Fate Therapeutics is way too risky over 90 days horizon | |
| Fate Therapeutics may become a speculative penny stock | |
| Fate Therapeutics appears to be risky and price may revert if volatility continues | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (102.19 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1745 shares by Ticho Barry of Stoke Therapeutics at 10.0 subject to Rule 16b-3 |
Fate Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fate Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fate Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Fate Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 162.78 M.Basic technical analysis of Fate Stock
As of the 6th of June, Fate Therapeutics shows the Coefficient Of Variation of 989.48, mean deviation of 5.78, and Downside Deviation of 7.33. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Fate Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 1.34 per share. Given that Fate Therapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.Fate Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fate Therapeutics' Outstanding Corporate Bonds
Fate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Fate Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Fate Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1773 | |||
| Market Risk Adjusted Performance | 1.75 | |||
| Mean Deviation | 5.78 | |||
| Semi Deviation | 6.87 | |||
| Downside Deviation | 7.33 | |||
| Coefficient Of Variation | 989.48 | |||
| Standard Deviation | 7.47 | |||
| Variance | 55.86 | |||
| Information Ratio | 0.1002 | |||
| Jensen Alpha | 0.7468 | |||
| Total Risk Alpha | 0.7607 | |||
| Sortino Ratio | 0.1021 | |||
| Treynor Ratio | 1.74 | |||
| Maximum Drawdown | 39.69 | |||
| Value At Risk | (10.69) | |||
| Potential Upside | 12.77 | |||
| Downside Variance | 53.78 | |||
| Semi Variance | 47.23 | |||
| Expected Short fall | (6.11) | |||
| Skewness | 0.3693 | |||
| Kurtosis | 0.891 |
| Risk Adjusted Performance | 0.1773 | |||
| Market Risk Adjusted Performance | 1.75 | |||
| Mean Deviation | 5.78 | |||
| Semi Deviation | 6.87 | |||
| Downside Deviation | 7.33 | |||
| Coefficient Of Variation | 989.48 | |||
| Standard Deviation | 7.47 | |||
| Variance | 55.86 | |||
| Information Ratio | 0.1002 | |||
| Jensen Alpha | 0.7468 | |||
| Total Risk Alpha | 0.7607 | |||
| Sortino Ratio | 0.1021 | |||
| Treynor Ratio | 1.74 | |||
| Maximum Drawdown | 39.69 | |||
| Value At Risk | (10.69) | |||
| Potential Upside | 12.77 | |||
| Downside Variance | 53.78 | |||
| Semi Variance | 47.23 | |||
| Expected Short fall | (6.11) | |||
| Skewness | 0.3693 | |||
| Kurtosis | 0.891 |
Consider Fate Therapeutics' intraday indicators
Fate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 50339.45 | |||
| Daily Balance Of Power | (0.89) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 1.39 | |||
| Day Typical Price | 1.37 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.08) | |||
| Relative Strength Index | 53.89 |
Fate Stock media impact
There is far too much social signal, news, headlines, and media speculation about Fate Therapeutics that are available to investors today. This information is accessible both publicly - through Fate Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Fate-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Fate Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fate Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fate Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fate Therapeutics alpha.
Fate Therapeutics Corporate Management
| Barbara Hickingbottom | Senior Development | Profile | |
| Tunde Babalola | Senior Operations | Profile | |
| Andrew Henry | Senior Operations | Profile | |
| Jessica Francis | Vice Operations | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Fate Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.